Invivyd Earnings Call Highlights Pivotal Trial Momentum

Invivyd ((IVVD)) has held its Q4 earnings call. Read on for the main highlights of the call.

Invivyd’s latest earnings call struck a cautiously optimistic tone, with management emphasizing accelerating PEMGARDA revenues, a fortified balance sheet, and clinical de‑risking in its pivotal COVID antibody program. While trial timing and epidemiological uncertainties remain, the overall message was that commercial traction and capital resources currently outweigh the operational risks.

PEMGARDA Revenue Growth

PEMGARDA continues to show solid commercial momentum, with Q4 2025 net revenues rising 31% quarter over quarter and 25% versus Q4 2024. For full-year 2025, the product generated $53.4 million in net revenues, underscoring meaningful market demand for COVID prophylaxis among vulnerable patients.

Strong Cash Position and Fundraising

Invivyd bolstered its financial position by raising more than $200 million in 2025 and ended the year with $226.7 million in cash and equivalents. Management said this cash runway is expected to fund the pivotal VYD2311 data readout in mid‑2026 and potentially beyond, assuming continued prudent spending and commercial execution.

Commercial Traction and Durable Demand

Commercial engagement around PEMGARDA appeared robust, with a 77% account reorder rate signaling durable demand and clinical satisfaction. The drug is now available across more than 15,000 contracted GPO sites, with growing use in hematology, oncology, rheumatology, infectious disease, transplant, neurology, and other high‑risk specialties.

Declaration Trial Enrollment Milestone

The Declaration pivotal trial for VYD2311 reached its target enrollment of roughly 1,770 subjects randomized 1:1:1:1 across three active arms and a placebo. The company reported that COVID event accrual has begun and is currently described as “on track,” an important prerequisite for assessing the antibody’s real‑world effectiveness.

Positive Safety/Tolerability IDMC Recommendations

The Independent Data Monitoring Committee delivered a series of favorable recommendations that effectively loosen safety‑related constraints in Declaration. Pregnant and breastfeeding women may now enroll, contraception requirements for women of childbearing age were dropped, and several early post‑dose safety visits were removed, all pointing to a reassuring initial tolerability profile.

VYD2311 Profile and Clinical Strategy

VYD2311 was highlighted as more potent in vitro than pemivibart and possessing a longer half‑life, with a formulation designed for intramuscular dosing to ease administration. Declaration is Invivyd’s third randomized, placebo‑controlled COVID monoclonal trial, and management continues to guide to pivotal data in Q2 or Q3 2026, assuming no major upsizing or event‑rate delays.

Pipeline Expansion and Targeted Indications

Beyond COVID prevention, Invivyd is expanding into related infectious and post‑infectious conditions to diversify its portfolio. The company is initiating clinical work in long COVID and post‑vaccine syndromes, has identified a highly potent RSV antibody seen as competitive with current standard of care, and plans a measles program update in the first half of 2026.

Regulatory and Guideline Momentum

Regulatory and guideline trends appear increasingly favorable for monoclonal antibody prophylaxis in high‑risk patients. PEMGARDA has been incorporated into NCCN guidelines for B‑cell lymphomas, and upcoming discussions by national advisory bodies on long COVID and post‑vaccine syndromes could further validate antibody‑based strategies if outcomes are supportive.

Uncertain Attack Rate and Potential Trial Upsizing

A key risk flagged on the call was Declaration’s dependence on real‑world COVID “attack rates,” which the company cannot control. If community infection rates are lower than assumed, a prespecified algorithm could trigger a roughly 30% increase in sample size, raising trial costs and potentially introducing timing friction around the pivotal readout.

Timing Ambiguity for Pivotal Data

Management framed pivotal Declaration data timing as mid‑year 2026, narrowed to a Q2 or Q3 window that hinges on both recruitment and event accrual. While they suggested that modest upsizing may not push beyond this window, any sustained slowdown in events could still blur the exact timing and may be watched closely by investors.

Safety Signal Monitoring Limitations (Myocarditis)

The company acknowledged limitations in its LIBERTY study’s ability to rule out rare myocarditis or pericarditis events, given the trial’s relatively small size. Because the myocarditis question often stems from comparisons with mRNA vaccines, management cautioned that very low‑frequency safety signals cannot be fully excluded at this stage.

Competitive and Scientific Uncertainty in RSV

Invivyd’s RSV program targets a market already served by entrenched products such as nirsevimab, which have established efficacy and commercial footprints. While management believes its candidate could be best‑in‑class based on potency, they emphasized that true differentiation and adoption will require rigorous clinical validation against these incumbent therapies.

Pipeline Programs Early-Stage and Conditional

The measles antibody initiative remains early, with potential uses such as outbreak prophylaxis or serving as a bridge to vaccination still largely conceptual. Similarly, long COVID and post‑vaccine syndrome efforts are in exploratory phases and will be influenced by evolving regulatory views and public‑health priorities, making timelines and economics uncertain.

Dependence on Continued Commercial Momentum

Management stressed that the current cash runway and strategic flexibility are tied to ongoing PEMGARDA growth and tight operational discipline. Any slowdown in uptake or missteps on spending could constrain the company’s ability to fully fund its expanding pipeline and late‑stage trials without additional capital.

Forward-Looking Guidance and Trial Outlook

Looking ahead, Invivyd expects Declaration to modestly over‑enroll and will run a prespecified upsizing analysis around April to decide if roughly 30% more patients are needed. Even with such an adjustment, management reiterated confidence that VYD2311’s pivotal data should land in the Q2–Q3 2026 window, underpinned by its superior potency profile and the encouraging commercial metrics reported for PEMGARDA.

Invivyd’s call painted a picture of a company transitioning from a single‑product COVID story to a broader infectious‑disease platform, financed at least through a pivotal inflection point. For investors, the key watch items will be PEMGARDA’s growth trajectory, Declaration event accrual, and early RSV and measles data, all set against a backdrop of manageable but real timing and competitive risks.